Report #2831777

Received Mar 17, 2025

A note on interpretation. VAERS reports are unverified and may be incomplete or coincidental. A report does not establish that a vaccine caused an event, and counts should not be used to calculate incidence or infer causation. Full disclaimer

Overview

Sex: Female
Age: Age unknown
State: NY
Recovered: Unknown
Vaccinated: Jan 13, 2025
Onset: Jan 13, 2025
Days to onset: 0
Hospital days: —

Vaccines (1)

Type	Name	Manufacturer	Dose	Lot	Route / Site
VARZOS	ZOSTER (SHINGRIX)	GLAXOSMITHKLINE BIOLOGICALS	2	UNK	—

Symptoms (1)

Inappropriate schedule of product administration

Symptom narrative

late dose; This non-serious case was reported by a pharmacist and described the occurrence of drug dose administration interval too long in a female patient who received Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 22-NOV-2022). On 13-JAN-2025, the patient received the 2nd dose of Shingrix. On 13-JAN-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: late dose). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 10-MAR-2025 The pharmacist reported that a patient received her first dose on 22-NOV-2022 and her second dose on 13-JAN-2025, which led to drug dose administration interval too long.